Does Betmiga (mirabegron) affect prostate-specific antigen (PSA) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Betmiga (Mirabegron) Does Not Affect PSA Levels

Mirabegron does not alter prostate-specific antigen (PSA) levels and can be safely used without requiring PSA adjustment or interpretation changes. This is fundamentally different from 5-alpha reductase inhibitors (finasteride, dutasteride), which significantly suppress PSA by approximately 50% and require doubling of PSA values for accurate interpretation 1.

Key Mechanistic Distinction

Mirabegron is a β3-adrenoceptor agonist that works on bladder smooth muscle to treat overactive bladder symptoms 2, 3, 4. Unlike 5-alpha reductase inhibitors that block DHT production—the primary driver of prostatic epithelial cell secretion and PSA production 1—mirabegron has no hormonal mechanism affecting prostate tissue or PSA secretion.

Clinical Evidence

The available research on mirabegron consistently measures PSA as a safety parameter in studies involving men with benign prostatic hyperplasia and prostate cancer patients, with no reported PSA alterations:

  • Studies in post-radical prostatectomy patients 3, 5 monitored PSA without noting any drug-related changes
  • Trials in elderly men (≥80 years) with multiple comorbidities 4 showed no PSA concerns
  • Combination therapy studies with alpha-blockers 2, 5 measured PSA routinely without identifying mirabegron-related effects

Contrast with Alpha-Blockers

Recent pharmacovigilance data suggests tamsulosin (an alpha-blocker) may actually increase PSA levels 6, though this requires further validation. This is clinically relevant since mirabegron is often combined with alpha-blockers in practice 2, 5.

Clinical Implications

You can:

  • Continue routine PSA screening without adjustment in patients taking mirabegron
  • Use standard PSA thresholds (4.0 ng/ml) for biopsy decisions 7
  • Apply normal PSA velocity calculations (>0.75 ng/ml/year concerning) 7, 1
  • Interpret PSA changes as you would in untreated patients

Critical caveat: If a patient is taking mirabegron plus a 5-alpha reductase inhibitor (finasteride/dutasteride), you must still apply the doubling rule or use the 0.3 ng/ml rise-from-nadir threshold for the 5ARI component 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.